NICE to work with company on addressing issues in appraisals of cannabidiol for treating difficult to control epilepsies
NICE has today (23 August 2019) announced its intention to work with GW Pharma to address the issues highlighted by its independent appraisal committee in its evaluation of cannabidiol for treating 2 types of severe treatment-resistant epilepsy.
-
Sir Andrew Dillon to stand down as NICE chief executive
Chief executive has been at the helm of the institute since it was founded in April 1999
-
NICE draft guidance and NHS England review highlight need for more research on cannabis-based medicinal products
NICE has today (8 August 2019) published its draft recommendations on the use of cannabis-based medicinal products following a comprehensive evaluation of their clinical and cost-effectiveness.
-
New lung cancer treatment option approved by NICE
Another new life-extending treatment for some people with lung cancer is to be made available on the Cancer Drugs Fund (CDF) following its approval by NICE in draft guidance published today (8 August 2019).
